litlas
ログインアカウント作成

Peter C. Taylor

1985–2025 年に発表

152
論文数
21,177
被引用数
86
h 指数
147
i10 指数

被引用数

Peter C. Taylor の年別被引用数1948 年: 被引用 1 件1988 年: 被引用 1 件1989 年: 被引用 1 件1990 年: 被引用 2 件1991 年: 被引用 3 件1992 年: 被引用 9 件1993 年: 被引用 2 件1994 年: 被引用 5 件1995 年: 被引用 15 件1996 年: 被引用 14 件1997 年: 被引用 34 件1998 年: 被引用 32 件1999 年: 被引用 34 件2000 年: 被引用 71 件2001 年: 被引用 129 件2002 年: 被引用 111 件2003 年: 被引用 121 件2004 年: 被引用 127 件2005 年: 被引用 98 件2006 年: 被引用 107 件2007 年: 被引用 124 件2008 年: 被引用 147 件2009 年: 被引用 155 件2010 年: 被引用 147 件2011 年: 被引用 120 件2012 年: 被引用 126 件2013 年: 被引用 133 件2014 年: 被引用 109 件2015 年: 被引用 132 件2016 年: 被引用 109 件2017 年: 被引用 135 件2018 年: 被引用 164 件2019 年: 被引用 505 件2020 年: 被引用 782 件2021 年: 被引用 805 件2022 年: 被引用 716 件2023 年: 被引用 573 件2024 年: 被引用 810 件2025 年: 被引用 467 件2026 年: 被引用 15 件1949〜1987 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,076 件、この内訳の 19.7%イギリス: 引用元論文 1,191 件、この内訳の 11.3%中国: 引用元論文 674 件、この内訳の 6.4%ドイツ: 引用元論文 560 件、この内訳の 5.3%イタリア: 引用元論文 516 件、この内訳の 4.9%フランス: 引用元論文 444 件、この内訳の 4.2%オランダ: 引用元論文 393 件、この内訳の 3.7%日本: 引用元論文 361 件、この内訳の 3.4%カナダ: 引用元論文 354 件、この内訳の 3.4%オーストラリア: 引用元論文 288 件、この内訳の 2.8%スペイン: 引用元論文 283 件、この内訳の 2.7%スウェーデン: 引用元論文 251 件、この内訳の 2.4%
0%19.7%その他 29.8%

機関

分野

  • Medicine66.3%
  • Biochemistry, Genetics and Molecular Biology14%
  • Immunology and Microbiology9.2%
  • Nursing4.1%
  • Neuroscience2.4%
  • Pharmacology, Toxicology and Pharmaceutics0.6%
  • その他3.4%

トピック

  • Rheumatoid Arthritis Research and Therapies11.1%
  • Systemic Lupus Erythematosus Research3.6%
  • Autoimmune and Inflammatory Disorders Research3.4%
  • Spondyloarthritis Studies and Treatments3.4%
  • Cytokine Signaling Pathways and Interactions2.5%
  • Monoclonal and Polyclonal Antibodies Research1.9%
  • その他74.1%

共著者

全論文

検索で開く
  1. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

    著者: Felice Rivellese, Anna E. A. Surace, Katriona Goldmann, Elisabetta Sciacca, Cankut Çubuk, Giovanni Giorli, Christopher R. John, Alessandra Nerviani, Liliane Fossati‐Jimack, Georgina Thorborn, Manzoor Ahmed, Edoardo Prediletto, S. Church, Briana M. Hudson, Sarah Warren, Paul McKeigue, Frances Humby, Michele Bombardieri, Michael R. Barnes, Myles Lewis, Costantino Pitzalis, the R4RA collaborative group, Felice Rivellese, Giovanni Giorli, Alessandra Nerviani, Liliane Fossati‐Jimack, Georgina Thorborn, Frances Humby, Michele Bombardieri, Myles Lewis, Patrick Durez, Maya H Buch, Hasan Rizvi, Arti Mahto, Carlomaurizio Montecucco, Bernard Lauwerys, Nora Ng, Pauline Ho, Vasco C. Romão, João Eurico Fonseca, Patrick Verschueren, Stephen Kelly, Pier Paolo Sainaghi, Nagui Gendi, Bhaskar DasGupta, Alberto Cauli, Piero Reynolds, Juan D. Cañete, Julio Ramírez, Raquel Celis, Robert J. Moots, Peter C. Taylor, C J Edwards, John D. Isaacs, Peter Sasieni, Ernest Choy, Charlotte Thompson, Serena Bugatti, Mattia Bellan, Mattia Congia, Christopher Holroyd, Arthur G. Pratt, Laura White, Louise Warren, Joanna Peel, Rebecca Hands, Gaye Hadfield, Costantino Pitzalis - Nature Medicine 2022 被引用: 279

  2. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

    著者: Peter C. Taylor, Edward Keystone, Désirée van der Heijde, Michael E. Weinblatt, Liliana Morales, Jaime Reyes Gonzaga, S. S. Yаkushin, Taeko Ishii, Kahaku Emoto, Scott D. Beattie, Vipin Arora, C. Gaich, Terence Rooney, Douglas Schlichting, William L. Macias, Stephanie de Bono, Yoshiya Tanaka - New England Journal of Medicine 2017 被引用: 951

  3. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

    著者: Frances Humby, Patrick Durez, Maya H Buch, Myles Lewis, Hasan Rizvi, Felice Rivellese, Alessandra Nerviani, Giovanni Giorli, Arti Mahto, Carlomaurizio Montecucco, Bernard Lauwerys, Nora Ng, Pauline Ho, Michele Bombardieri, Vasco C. Romão, Patrick Verschueren, Stephen Kelly, Pier Paolo Sainaghi, Nagui Gendi, Bhaskar Dasgupta, Alberto Cauli, Piero Reynolds, Juan D. Cañete, Robert J. Moots, Peter C. Taylor, Christopher J Edwards, John D. Isaacs, Peter Sasieni, Ernest Choy, Costantino Pitzalis, Charlotte Thompson, Serena Bugatti, Mattia Bellan, Mattia Congia, Christopher Holroyd, Arthur G. Pratt, João Eurico Fonseca, Laura White, Louise Warren, Joanna Peel, Rebecca Hands, Liliane Fossati‐Jimack, Gaye Hadfield, Georgina Thorborn, Julio Ramírez, Raquel Celis - The Lancet 2021 被引用: 315

  4. Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes

    著者: Myles Lewis, Michael R. Barnes, Kevin Blighe, Katriona Goldmann, Sharmila Rana, Jason A. Hackney, Nandhini Ramamoorthi, Christopher R. John, David Watson, Sarah Kummerfeld, Rebecca Hands, Sudeh Riahi, Vidalba Rocher-Ros, Felice Rivellese, Frances Humby, Stephen Kelly, Michele Bombardieri, Nora Ng, Maria DiCicco, Désirée van der Heijde, Robert Landewé, Annette H M van der Helm–van Mil, Alberto Cauli, Iain B. McInnes, Christopher D. Buckley, Ernest Choy, Peter C. Taylor, Michael J. Townsend, Costantino Pitzalis - Cell Reports 2019 被引用: 416

  5. Neutralizing monoclonal antibodies for treatment of COVID-19

    著者: Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, Inmaculada de la Torre, Kevin Winthrop, Robert Gottlieb - Nature reviews. Immunology 2021 被引用: 794

  6. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients

    著者: Frances Humby, Myles Lewis, Nandhini Ramamoorthi, Jason A. Hackney, Michael R. Barnes, Michele Bombardieri, Audi Setiadi, Stephen Kelly, Fabiola Bene, Maria DiCicco, Sudeh Riahi, Vidalba Rocher, Nora Ng, Ilias Lazarou, Rebecca Hands, Désirée van der Heijde, Robert Landewé, Annette H M van der Helm–van Mil, Alberto Cauli, Iain B. McInnes, Christopher D. Buckley, Ernest Choy, Peter C. Taylor, Michael J. Townsend, Costantino Pitzalis - Annals of the Rheumatic Diseases 2019 被引用: 326

  7. The Jak/STAT pathway: A focus on pain in rheumatoid arthritis

    著者: Lee S. Simon, Peter C. Taylor, Ernest Choy, Anthony Sebba, Amanda Quebe, Kelly L. Knopp, Frank Porreca - Seminars in Arthritis and Rheumatism 2020 被引用: 215

  8. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

    著者: Peter C. Taylor, Tsutomu Takeuchi, Gerd R Burmester, Patrick Durez, Josef S Smolen, Walter Deberdt, Maher Issa, Jorge Ross Terrés, Natalia Bello, Kevin Winthrop - Annals of the Rheumatic Diseases 2021 被引用: 160

  9. Anti-TNF therapy: past, present and future

    著者: Claudia Monaco, Jagdeep Nanchahal, Peter C. Taylor, Marc Feldmann - International Immunology 2014 被引用: 571

  10. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations

    著者: Iain B. McInnes, Nicole L Byers, Richard E. Higgs, Jonathan Lee, William L. Macias, Songqing Na, Robert Ortmann, Guilherme Rocha, Terence Rooney, Thomas S. Wehrman, Xin Zhang, Steven H. Zuckerman, Peter C. Taylor - Arthritis Research & Therapy 2019 被引用: 281

  11. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases

    著者: Peter C. Taylor, Ernest Choy, Xenofon Baraliakos, Zoltán Szekanecz, Ricardo Machado Xavier, John D. Isaacs, Sander Strengholt, Julie Parmentier, Ralph Lippe, Yoshiya Tanaka - Lara D. Veeken 2023 被引用: 93

  12. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial

    著者: José María Álvaro‐Gracia, Juan Ángel Jover, Rosario García‐Vicuña, Luis Carreño, Alberto Alonso, Sara Marsal, Francisco J. Blanco, Víctor M. Martínez‐Taboada, Peter C. Taylor, Cristina Martín-Martín, Olga DelaRosa, Ignacio Tagarro, Federico Díaz‐González - Annals of the Rheumatic Diseases 2016 被引用: 263

  13. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review

    著者: Peter C. Taylor, Fabiola Atzeni, Alejandro Balsa, Laure Gossec, Ulf Müller‐Ladner, Janet Pope - Journal of Clinical Medicine 2021 被引用: 109

  14. Alterations in the gut microbiome implicate key taxa and metabolic pathways across inflammatory arthritis phenotypes

    著者: Kelsey N. Thompson, Kevin S. Bonham, Nicholas E. Ilott, Graham J. Britton, Paula Colmenero, Samuel J. Bullers, Lauren J. McIver, Siyuan Ma, Long H. Nguyen, Andrew Filer, India Brough, Claire Pearson, Caroline Moussa, Vinod Kumar, Lilian H. Lam, Matthew Jackson, April Pawluk, Serafim Kiriakidis, Peter C. Taylor, Lucy R. Wedderburn, Brian D. Marsden, Stephen P. Young, Dan R. Littman, Jeremiah J. Faith, Arthur G. Pratt, Paul Bowness, Karim Raza, Fiona Powrie, Curtis Huttenhower, Coziana Ciurtin, Claudia Mauri - Science Translational Medicine 2023 被引用: 49

  15. A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

    著者: Kathleen Weisel, Scott B. Berger, Katie Thorn, Peter C. Taylor, Charles Peterfy, Hilary K. Siddall, Debra Tompson, Susanne Wang, Emilia Quattrocchi, Susan W. Burriss, Jochen Walter, Paul P. Tak - Arthritis Research & Therapy 2021 被引用: 89

  16. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials

    著者: Felice Rivellese, Alessandra Nerviani, Giovanni Giorli, Louise Warren, Edyta Jaworska, Michele Bombardieri, Myles Lewis, Frances Humby, Arthur G. Pratt, Andrew Filer, Nagui Gendi, Alberto Cauli, Ernest Choy, Iain B. McInnes, Patrick Durez, Christopher J Edwards, Maya H Buch, Elisa Gremese, Peter C. Taylor, Nora Ng, Juan D. Cañete, Sabrina Raizada, Neil D McKay, Deepak R. Jadon, Pier Paolo Sainaghi, Richard Stratton, Michael R. Ehrenstein, Pauline Ho, Joaquim Polido‐Pereira, Bhaskar Dasgupta, Claire Gorman, James Galloway, Hector Chinoy, Désirée van der Heijde, Peter Sasieni, Anne Barton, Costantino Pitzalis, Ahmed S Zayat, Ana Rita Marinho Machado, Andrea Cuervo, Arti Mahto, Cankut Çubuk, Charlotte Rawlings, Chijioke H Mosanya, Christopher D. Buckley, Chris Holroyd, Debbie Maskall, Francesco Carlucci, Georgina Thorborn, Gina Tan, Gloria Lliso-Ribera, Hasan Rizvi, Joanna Peel, João Eurico Fonseca, John D. Isaacs, Julio Ramírez, Laurent Méric de Bellefon, Liliane Fossati-Jimak, Mary Ng’endo Githinji, Mattia Congia, Neal L. Millar, Nirupam Purkayastha, Raquel Celis, Rakhi Seth, Rebecca Hands-Greenwood, Robert Landewé, Simone Perniola, Stefano Alivernini, Stefano Marcia, Stefano Marini, Stephen Kelly, Vasco C. Romão - The Lancet Rheumatology 2023 被引用: 68

  17. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

    著者: Edward Keystone, Peter C. Taylor, Edit Drescher, Douglas Schlichting, Scott D. Beattie, Pierre‐Yves Berclaz, Chin H. Lee, Rosanne Fidelus-Gort, Monica Luchi, Terence Rooney, William L. Macias, Mark C. Genovese - Annals of the Rheumatic Diseases 2014 被引用: 282

  18. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

    著者: Peter C. Taylor, Michael E. Weinblatt, Gerd R Burmester, Terence Rooney, Sarah Witt, Chad D. Walls, Maher Issa, Claudia A. Salinas, Chadi Saifan, Xin Zhang, Anabela Cardoso, Miguel Á. González‐Gay, Tsutomu Takeuchi - Arthritis & Rheumatology 2019 被引用: 177

  19. Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC)

    著者: Gloria Lliso-Ribera, Frances Humby, Myles Lewis, Alessandra Nerviani, Daniele Mauro, Felice Rivellese, Stephen Kelly, Rebecca Hands, Fabiola Bene, Nandhini Ramamoorthi, Jason A. Hackney, Alberto Cauli, Ernest Choy, Andrew Filer, Peter C. Taylor, Iain B. McInnes, Michael J. Townsend, Costantino Pitzalis - Annals of the Rheumatic Diseases 2019 被引用: 128

  20. Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans

    著者: David R. Owen, Nehal Narayan, Lisa Wells, Luke M. Healy, Erica Smyth, Eugenii A. Rabiner, Dylan A. Galloway, John B. Williams, Joshua Lehr, Harpreet Mandhair, Laura A. N. Peferoen, Peter C. Taylor, Sandra Amor, Jack P. Antel, Paul M. Matthews, Craig S. Moore - Journal of Cerebral Blood Flow & Metabolism 2017 被引用: 199

  21. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

    著者: René Westhovens, Peter C. Taylor, Rieke Alten, Д. Е. Павлова, Favio Enríquez-Sosa, Minodora Mazur, Maria Greenwald, Annegret Van der Aa, Frédéric Vanhoutte, Chantal Tasset, Pille Harrison - Annals of the Rheumatic Diseases 2016 被引用: 234

  22. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis

    著者: Peter C. Taylor - Lara D. Veeken 2018 被引用: 171

  23. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

    著者: Daniel C. Baumgart, L. Misery, Sue Naeyaert, Peter C. Taylor - Frontiers in Pharmacology 2019 被引用: 134

  24. Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial

    著者: Peter C. Taylor, Yvonne Lee, Roy Fleischmann, Tsutomu Takeuchi, Elizabeth L. Perkins, Bruno Fautrel, Baojin Zhu, Amanda Quebe, C. Gaich, Xiang Zhang, Christina Dickson, Douglas Schlichting, Himanshu J. Patel, Frédérick Durand, Paul Emery - Journal of Clinical Medicine 2019 被引用: 91